Urogen Pharma Ltd

This proposal asks shareholders to approve an amended and restated set of Articles of Association that, among other things, ties the eligibility to request that matters be placed on the shareholder meeting agenda to the requirements of the Israeli Companies Law and implements several conforming technical and governance clarifications. Management is seeking shareholder approval to ensure that the Company’s governing documents are consistent with the Companies Law (including regulatory amendments effective in March 2024 changing thresholds for certain shareholder nomination rights for Israeli companies listed abroad) and to avoid future inconsistencies if the Companies Law is further amended. Key substantive changes include aligning shareholder proposal rights with statutory thresholds, clarifying the Board’s authority to issue ‘‘other securities’’ (beyond warrants and options), adjusting quorum language to focus on presence at the start of business, clarifying appointment authority for certain officers, and updating indemnification and insurance provisions to reflect current Israeli law. The Board frames this as largely conforming and housekeeping in nature, intended to preserve flexibility and legal conformity rather than to change shareholder substantive rights beyond alignment with the law. Shareholders should weigh that the change will limit (or formalize) the ability for small holders to force director nominations in a manner consistent with Israeli statutory thresholds, which could reduce the ability of small activist holders to add items without meeting the higher requirements. The board’s unanimous recommendation is supported by the rationale that the change reduces legal risk and administrative friction and ensures consistency with legal duties and listing practices. From a governance perspective, the amendment is typical for Israeli-incorporated, US-listed companies and reduces legal ambiguity; however, investors focused on shareholder access should note the adjustment to nomination thresholds. Given that the amendment is presented as conforming to law and clarifying existing practices, the board’s justification is reasonable but shareholders should confirm the detailed marked-up Articles (Appendix A-2) to understand any drafting nuances that could have practical effects.

This proposal requests shareholder approval of targeted amendments to the Company’s Compensation Policy to expressly clarify that directors and officers are eligible for insurance, exculpation and indemnification to the fullest extent permitted by law and to specify certain insurance features. Under Israeli law, insurance and indemnification arrangements are considered forms of compensation and thus, as a technical matter, require inclusion in the Company’s compensation policy and in some cases shareholder approval. The amendment explicitly permits the Compensation Committee (and the Board where required) to determine coverage amounts, allows for run‑off/tail insurance and Public Offering of Securities Insurance (POSI) and limits tail periods to a defined maximum, while imposing constraints so the annual premium and deductible are market‑rate and that policy costs not materially impact the Company’s financial position. Management frames this as aligning the policy with market practices among Israeli‑incorporated public companies and providing certainty that the Company can procure commercially appropriate D&O insurance (including POSI/run‑off) without needless procedural delays. Shareholders should note this is largely protective for directors/officers and customary, but because Israeli law treats these protections as compensation, shareholder approval confirms governance oversight of these arrangements; the proxy also notes the Board could adopt the amendment without shareholder approval under certain conditions, but seeks shareholder ratification to follow best practice and transparency. The Board recommends FOR as it views the change as necessary to attract and retain qualified directors and officers, reduce personal liability risk, and maintain market‑standard insurance coverages while constraining cost and ensuring oversight by the Compensation Committee.

This proposal asks shareholders to authorize an additional 1,000,000 ordinary shares under the Company’s 2017 Equity Incentive Plan to replenish the pool available for equity awards. Management contends equity awards are central to recruiting, retaining and aligning employees and directors with shareholder interests, and the requested increase follows substantial prior additions and recent granting activity; if approved, the plan’s total authorized reserve (after prior increases) will reach the stated maximum in the proxy. The Amended Plan includes anti‑dilution and governance features meant to limit shareholder exposure: no repricing without shareholder approval, no evergreen mechanism (fixed reserve requiring shareholder approval for increases), no single‑trigger change‑in‑control acceleration, limits on share recycling for withholding/exercise, and clawback provisions. The board emphasizes the size of the requested increase is reasonable relative to current available shares and recent burn rates and discloses current outstanding awards, overhang metrics, and the company’s grant history — useful for assessing dilution. From a governance and stewardship perspective, the plan preserves flexibility for compensation design while imposing several investor‑friendly constraints; however, shareholders should model the potential dilution impact and evaluate historical grant pacing and director/executive allocations against peer practices. The Board recommends FOR citing the need to retain talent and maintain competitive equity programs; the proxy further notes intent to register the additional shares on Form S‑8 if approved. Given the combination of pro‑shareholder plan features and the Company’s stated talent and retention needs during commercialization and product launches, the board’s rationale is typical, but investors should weigh dilution against expected value creation from product sales and milestones.

This advisory proposal asks shareholders to approve, on a non‑binding basis, the compensation paid to the named executive officers as disclosed in the proxy. Management seeks this periodic advisory endorsement to validate its pay philosophy, which it describes as pay‑for‑performance and heavily weighted toward equity and performance stock units tied to product sales and regulatory milestones. The proxy presents specifics: target bonus percentages, long‑term equity mix (including PSUs tied to cumulative net product sales and regulatory milestones), and that CEO pay was positioned near the 20th percentile of a defined peer group in 2025; it also references robust shareholder engagement, including outreach to holders representing over 80% of outstanding shares. The Board notes last year’s say‑on‑pay received strong support (over 89%), and commits to consider vote outcomes in future compensation decisions. For investors evaluating governance alignment, key considerations include the extent to which performance metrics are measurable and tied to long‑term value creation (e.g., cumulative product sales and regulatory milestones), clawback policies and limits on tax‑grossups, severance/change‑in‑control provisions, and the overall mix of cash vs. equity compensation. The advisory nature means the Board retains discretion but uses results as input; a negative vote would typically prompt further engagement and potential adjustments. Management recommends FOR to reaffirm its compensation approach and its alignment with strategic commercialization and development priorities.